Ocata Therapeutics, Inc.(NASDAQ : ACTC)
ACTC After-Hours: () as of PM
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Health Technology » Pharmaceuticals Major
Ocata Therapeutics, Inc. is a biotechnology company, engaged in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. It is actively conducting clinical trials for treating dry age-related macular degeneration and Stargardt's macular degeneration, in addition to several clinical and preclinical programs for other ocular therapies. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cell, or hESC; induced pluripotent stem cell, or iPSC, platforms; and other cell therapy research programs. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA.